"2022 has been a transformative year for the Company despite some challenging headwinds with the economy and financial markets."
Here's an abbreviated summary from today's Annual Shareholders Letter:
February-April 2022: received $40M+ from multiple offerings
April 2022: announced biopharma pipeline developments for mRNA molecules capable of destroying multidrug resistant cancer cells grown in culture. These mRNA molecules bear the laboratory designation K1.1.
July 2022: expanded collaboration with the University of Arizona to accelerate the development of our novel PLpro inhibitors for our anti-Coronavirus treatment program.
October 2022: acquired Canadian generic pharmaceuticals company, Nora Pharma Inc., with sales of approximately $14 million. Sunshine Biopharma now has over 50 generic prescription drugs on the market in Canada with plans to grow further throughout North America and potentially other markets around the world.
November 2022: vigorously pushed forward with our oncology K1.1 mRNA development program by entering into a key collaboration arrangement with a leading lipid nano-particle (LNP) formulation company in North America. Beginning in March, 2023, our partner generated K1.1-LNP formulations will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers as well as liver cancer. Should these mice studies prove successful, the Company can advance relatively rapidly to conducting human trials.
2023: objectives going forward will be focused on achieving profitability and investing in our proprietary drug development program.
